secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2021-09-29T23:59:59+00:00
Accession:  0001437749-21-022843
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex appoints Dr. Mark Berger as CMO, Dr. Hemant Kumar as CTO; COO Redman's role reduced
--------------------------------------------------------------------------------

- Mark Berger, MD appointed Chief Medical Officer; Hemant Kumar, PhD appointed Chief Manufacturing and Technology Officer.
- Michael Redman, EVP and COO, no longer oversees clinical and manufacturing operations; company in discussions for alternate role.
- Appointments effective September 2021 as disclosed in prior 8-K filed September 28, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774921022843/0001437749-21-022843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774921022843/gnpx20210929_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-022843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer